Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

Analyst Ratings

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (?)
Ratings Breakdown: 6 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $17.63 (18.74% downside)

Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Raymond James Financial Inc.DowngradeBuy -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Royal Bank Of CanadaDowngradeOutperform -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$22.00 -> $21.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Jefferies GroupReiterated RatingHold$13.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Bank of America Corp.Reiterated RatingHold$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016Deutsche Bank AGLower Price TargetBuy$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Needham & Company LLCDowngradeBuy -> Hold$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2014S&P Equity ResearchDowngradeBuy -> Neutral$25.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013($0.03)$0.10ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161($0.19)($0.19)($0.19)
Q3 20161$0.19$0.19$0.19
Q4 20161$0.35$0.35$0.35
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateHeadline
07/22/16 06:09 PMIs $21.75 Price Target Attainable For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? - Investor Newswire
07/22/16 06:09 PMStock Observed in Overbought Territory: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph
07/22/16 06:09 PMSagent Pharmaceuticals Incorporated (NASDAQ:SGNT) Sellers Increased By 21.86% Their Shorts - Press Telegraph
07/22/16 10:48 AMINVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. - [Business Wire] - The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc. in connection with the sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.
07/21/16 06:44 PMAcquisition of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Under Investigation for Investors
07/20/16 07:18 PMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors …
07/20/16 03:16 PMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Regarding the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. - SGNT - [PR Newswire] - NEW YORK, July 20, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) ("Sagent Pharmaceuticals" ...
07/20/16 09:17 AMSagent Pharmaceuticals, Inc. (NASDAQ:SGNT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 09:17 AMSagent Pharmaceuticals (SGNT) Launches Amikacin Sulfate Injection, USP - StreetInsider.com
07/20/16 09:17 AMAnalyst's Valuable Buzzers: Medtronic plc (NYSE:MDT) , Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Street Updates
07/19/16 01:02 PMINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information - [Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sagent Pharmaceuticals, Inc.
07/18/16 02:24 PMTrading Performance and Target Watch for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph
07/18/16 02:24 PMStock in Positive Territory for the Quarter: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Engelwood Daily
07/18/16 02:24 PMSagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP - GlobeNewswire (press release)
07/18/16 11:55 AMINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Sagent Pharmaceuticals, Inc. to Nichi-Iko Pharmaceutical Co., Ltd. for $21.75 Per Share is Fair to Shareholders - [Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:
07/18/16 07:29 AM8:29 am Sagent Pharma launches Amikacin Sulfate Injection, USP in 500 mg per 2 mL and 1 g per 4 mL preservative-free vials -
07/18/16 07:00 AMSagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP - [GlobeNewswire] - SCHAUMBURG, Ill., July 18, 2016-- Sagent Pharmaceuticals, Inc. today announced the launch of Amikacin Sulfate Injection, USP, an anti-infective/antibiotic, in 500 mg per 2 mL and 1 g per 4 mL preservative-free ...
07/17/16 05:45 PMSAGENT SHAREHOLDER NOTICE: Faruqi & Faruqi,...
07/15/16 05:21 PMSagent Pharmaceuticals Inc : Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Sagent Pharmaceuticals, Inc. - SGNT
07/15/16 05:05 PMSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Sagent Pharmaceuticals, Inc. - SGNT - [Accesswire] - BALA CYNWYD, PA / ACCESSWIRE / July 15, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc. ("Sagent" ...
07/15/16 11:37 AMStrong Sell Calls For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) At 0 - Investor Newswire
07/15/16 11:37 AMSagent Pharmaceuticals (SGNT): Price Target and June Short Interest Disclosure - Trade Calls
07/14/16 10:00 AMSagent Pharmaceuticals Inc. (SGNT) is Trading Higher on Unusual Volume for July 12 - Equities.com
07/13/16 06:47 PMShares Reaching Overbought Territory: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph
07/13/16 04:15 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning the Sale of Sagent Pharmaceuticals, Inc. to Nichi-Iko Pharmaceutical Co., Ltd. for $21.75 Per Share is Fair to Shareholders -- SGNT - [PR Newswire] - NEW YORK, July 13, 2016 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sagent Pharmaceuticals, Inc. ("Sagent") (NASDAQ: ...
07/13/16 09:16 AMWatching Unusual Volume on Shares of: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Engelwood Daily
07/13/16 09:16 AMSagent Pharmaceuticals Inc. (SGNT) Jumps 39.68% on July 11 - Equities.com
07/12/16 06:36 PMSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Sagent Pharmaceuticals, Inc. -SGNT
07/12/16 06:36 PMTop Japanese Generic Drug Maker to Acquire Sagent (SGNT)
07/12/16 06:36 PMSagent Pharmaceuticals Inc. (SGNT) Leaped After Bought By Nichi-Iko
07/12/16 06:36 PMSAGENT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sagent Pharmaceuticals, …
07/12/16 04:23 PMSAGENT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sagent Pharmaceuticals, Inc. (SGNT) Over the Proposed Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. - [PR Newswire] - NEW YORK, July 12, 2016 /PRNewswire/ -- Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP , a leading national securities firm headquartered in New York City, is investigating the Board of Directors ...
07/12/16 04:09 PMSagent Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of SGNT Shareholders - [PR Newswire] - NEW YORK, July 12, 2016 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Sagent Pharmaceuticals, Inc. ("SGNT" ...
07/12/16 11:40 AMINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into the Sale of Sagent Pharmaceuticals, Inc. to Nichi-Iko Pharmaceutical Co., Ltd. for $21.75 Per Share is Fair to Shareholders -- SGNT - [Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:
07/12/16 10:46 AMDrug Generic in Top Gainers- Sagent Pharmaceuticals (NASDAQ:SGNT), Lannett Firm (NYSE:LCI) - Seneca Globe
07/12/16 10:46 AMPre Session Movers- Sagent Pharmaceuticals (NASDAQ:SGNT), Telefonica (NYSE:TEF), United Technologies (NYSE ... - Seneca Globe
07/12/16 10:46 AMHC Stocks Highlights: Sagent Pharmaceuticals Inc (NASDAQ:SGNT), Palatin Technologies, Inc. (NYSEMKT:PTN) - share market updates (press release)
07/12/16 10:46 AMSagent Pharmaceuticals (NASDAQ:SGNT) & Marriott International (NASDAQ:MAR) Worth Watching Stocks - Money News (press release)
07/12/16 10:07 AMRyan & Maniskas, LLP Announces Investigation of Sagent Pharmaceuticals, Inc. - [PR Newswire] - WAYNE, Pa., July 12, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company") ...
07/11/16 06:46 PMBenzinga's M&A Chatter for Monday July 11, 2016 - The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday July 11, 2016: Nichi-Iko Pharmaceutical Co. to Acquire Sagent Pharmaceuticals for $21.75/Share in Cash The Deal:Nichi-Iko Pharmaceutical Co., Ltd (OTC: NHKFF) and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) announced Monday, that they have entered into a definitive merger agreement under which Nichi-Iko will acquire Sagent via an all-cash tender offer for $21.75 per share, for a total consideration of approximately $736 million. The acquisition is not subject to any financing condition. Sagent Pharmaceuticals closed at $21.65 on Monday, up ...Full story available on Benzinga.com
07/11/16 06:18 PMEarly Movers: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), iShares MSCI ACWI (NASDAQ:ACWI), Apple Inc ... - KC Register
07/11/16 06:18 PMMid-Day Market Update: Dow Surges Over 100 Points; Sagent Pharmaceuticals Shares Spike Higher - Benzinga
07/11/16 06:18 PMStock Pushing HIgher in Session: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Telanagana Press
07/11/16 06:18 PMRBC Capital Cuts Rating On Sagent Pharmaceuticals, Inc. (SGNT) - Finance Daily
07/11/16 06:18 PMShares Noted in Overbought Territory: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph
07/11/16 06:18 PMSagent Pharmaceuticals Inc (SGNT) Stock Skyrockets on Nichi-Iko's Buyout Offer - Bidness ETC
07/11/16 10:59 AMMid-Morning Market Update: Markets Open Higher; Bank Of The Ozarks Profit Tops Views
07/11/16 10:59 AMSagent Pharmaceuticals (SGNT) Leaps on Takeover by Nichi-Iko
07/11/16 10:59 AMNichi-Iko Pharma to Acquire Sagent Pharmaceuticals (SGNT) in $736M Deal
07/11/16 10:59 AMSagent Pharmaceuticals Inc. (SGNT) Is Soaring After Bought By Nichi-Iko

Social

About Sagent Pharmaceuticals

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SGNT
  • CUSIP: 78669210
Key Metrics:
  • Previous Close: $21.69
  • 50 Day Moving Average: $16.70
  • 200 Day Moving Average: $14.08
  • P/E Ratio: N/A
  • P/E Growth: 2.66
  • Market Cap: $712.26M
  • Beta: 1.47
  • Current Year EPS Consensus Estimate: $0.25 EPS
  • Next Year EPS Consensus Estimate: $0.74 EPS
Additional Links:
Sagent Pharmaceuticals (NASDAQ:SGNT) Chart for Monday, July, 25, 2016